These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35339277)

  • 1. A Commotion in the Skin: Developing Melanoma Immunotherapies.
    Brenner E; Röcken M
    J Invest Dermatol; 2022 Aug; 142(8):2055-2060. PubMed ID: 35339277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma antigens recognized by T cells and their use for immunotherapy.
    Ohta S; Misawa A; Kyi-Tha-Thu C; Matsumoto N; Hirose Y; Kawakami Y
    Exp Dermatol; 2023 Mar; 32(3):297-305. PubMed ID: 36607252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vaccine strategies against melanoma].
    Ghiringhelli F; Zitvogel L
    Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Immunotherapy for Melanoma: A Comprehensive Review.
    Rodríguez-Cerdeira C; Carnero Gregorio M; López-Barcenas A; Sánchez-Blanco E; Sánchez-Blanco B; Fabbrocini G; Bardhi B; Sinani A; Guzman RA
    Mediators Inflamm; 2017; 2017():3264217. PubMed ID: 28848246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
    Zikich D; Schachter J; Besser MJ
    Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
    Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
    Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor rejection antigen and cancer immunotherapy].
    Matsutake T; Nakayama E
    Gan To Kagaku Ryoho; 1995 Nov; 22(13):1871-7. PubMed ID: 7487115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to overcome obstacles to successful immunotherapy of melanoma.
    Pandolfi F; Cianci R; Lolli S; Dunn IS; Newton EE; Haggerty TJ; Boyle LA; Kurnick JT
    Int J Immunopathol Pharmacol; 2008; 21(3):493-500. PubMed ID: 18831916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
    Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
    J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor antigen targets and tumor immunotherapy.
    Mufson RA
    Front Biosci; 2006 Jan; 11():337-43. PubMed ID: 16146735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
    Rosenberg SA
    Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
    Melis C; Rogiers A; Bechter O; van den Oord JJ
    Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.